- Esbriet posted sales of about $230 million last year
- Esbriet is used for treating a chronic lung disease called IPF
Roche Holding AG is considering selling Esbriet, a lung disease drug that’s seen sales plummet amid competition from cheaper generics.
The Swiss pharmaceuticals giant is in the early stages of evaluating a disposal after getting inbound interest from potential suitors, people with knowledge of the matter said, asking not to be identified discussing confidential information.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.